Princess Kate's public return post-chemotherapy reveals her resilience and dedication to royal duties. Her actions highlight a stark contrast with Meghan Markle's public behavior, showcasing quiet strength and commitment.
AstraZeneca's IMFINZI® combined with chemotherapy has gained FDA approval for treating mismatch repair deficient advanced or recurrent endometrial cancer, significantly improving patient outcomes. The approval is based on the successful DUO-E Phase III trial, which demonstrated a 58% reduction in disease progression or death compared to chemotherapy alone.
Acute Myeloid Leukemia (AML) is on the rise, prompting biotechs to accelerate the development of groundbreaking therapies. With advances in research, technology, and government support, the AML market is seeing significant growth and innovation.
